Patents by Inventor Mark R. Alderson

Mark R. Alderson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7138500
    Abstract: Novel 4-1BB ligand (4-1BB-L) polypeptides and a human cell surface receptor designated 4-1BB that binds 4-1BB-L are provided. Isolated 4-1BB-L-encoding and human 4-1BB-encoding DNA sequences, recombinant expression vectors comprising the isolated DNA sequences, and host cells transformed with the recombinant expression vectors are disclosed, along with methods for producing the novel polypeptides by cultivating such transformed host cells. Soluble forms of the 4-1BB-L or 4-1BB polypeptides are derived from the extracellular domains thereof.
    Type: Grant
    Filed: September 10, 1998
    Date of Patent: November 21, 2006
    Assignee: Immunex Corporation
    Inventors: Raymond G. Goodwin, Craig A. Smith, Mark R. Alderson
  • Publication number: 20020081579
    Abstract: Methods for isolating novel antigens that stimulate CD4-positive T cells are disclosed. The methods provided comprise the steps of: transforming a host cell with a plasmid suspected of containing such a DNA sequence encoding such an antigen and inducing antigen expression; incubating the transformed host cell with at least one dendritic cell for a period of time sufficient to form a peptide/MHC Class II complex on the dendritic cell, the peptide being derived from the expressed antigen; incubating the dendritic cell with CD4+ T cells; determining the level of CD4+ T cell stimulation, thereby identifying a transformed host cell that expresses at least one CD4+ T cell-stimulating antigen; and isolating DNA from the transformed host cell. DNA sequences isolated using such methods, together with antigens encoded by such DNA sequences, are also provided.
    Type: Application
    Filed: February 13, 1998
    Publication date: June 27, 2002
    Applicant: Jane E. R. Potter
    Inventors: YASIR A.W. SKEIKY, DAVIN C. DILLON, MARK R. ALDERSON
  • Patent number: 6355779
    Abstract: Novel 4-1BB ligand (4-1BB-L) polypeptides and a human cell surface receptor designated 4-1BB that binds 4-1BB-L are provided. Isolated 4-1BB-L-encoding and human 4-1BB-encoding DNA sequences, recombinant expression vectors comprising the isolated DNA sequences, and host cells transformed with the recombinant expression vectors are disclosed, along with methods for producing the novel polypeptides by cultivating such transformed host cells. Soluble forms of the 4-1BB-L or 4-1BB polypeptides are derived from the extracellular domains thereof.
    Type: Grant
    Filed: September 10, 1998
    Date of Patent: March 12, 2002
    Assignee: Immunex Corporation
    Inventors: Raymond G. Goodwin, Craig A. Smith, Mark R. Alderson
  • Publication number: 20010012888
    Abstract: Compounds and methods for diagnosing tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of one or more M. tuberculosis proteins, and DNA sequences encoding such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable detection reagent may be used for the detection of M. tuberculosis infection in patients and biological samples. Antibodies directed against such polypeptides are also provided.
    Type: Application
    Filed: May 5, 1998
    Publication date: August 9, 2001
    Inventors: MARK R. ALDERSON, DAVIN C. DILLON, YASIR A.W. SKEIKY, ANTONIO CAMPOS-NETO
  • Patent number: 6015559
    Abstract: The present invention provides a panel of monoclonal antibodies and binding proteins which specifically bind to human Fas antigen. Some of the antibodies and binding proteins are capable of stimulating T cell proliferation, inhibiting binding of anti-Fas CH-11 monoclonal antibody to cells expressing Fas antigen, blocking anti-Fas CH-11 monoclonal antibody-mediated lysis of cells, and blocking Fas ligand-mediated lysis of cells. The invention also provides for therapeutic compositions comprising the monoclonal antibodies.
    Type: Grant
    Filed: September 14, 1998
    Date of Patent: January 18, 2000
    Assignee: Immunex Corporation
    Inventors: David H. Lynch, Mark R. Alderson
  • Patent number: 5830469
    Abstract: The present invention provides a panel of monoclonal antibodies and binding proteins which specifically bind to human Fas antigen. Some of the antibodies and binding proteins are capable of stimulating T cell proliferation, inhibiting binding of anti-Fas CH-11 monoclonal antibody to cells expressing Fas antigen, blocking anti-Fas CH-11 monoclonal antibody-mediated lysis of cells, and blocking Fas ligand-mediated lysis of cells. The invention also provides for therapeutic compositions comprising the monoclonal antibodies.
    Type: Grant
    Filed: April 26, 1995
    Date of Patent: November 3, 1998
    Assignee: Immunex Corporation
    Inventors: David H. Lynch, Mark R. Alderson
  • Patent number: 5674704
    Abstract: Novel 4-1BB ligand (4-1BB-L) polypeptides and a human cell surface receptor designated 4-1BB that binds 4-1BB-L are provided. Isolated 4-1BB-L-encoding and human 4-1BB-encoding DNA sequences, recombinant expression vectors comprising the isolated DNA sequences, and host cells transformed with the recombinant expression vectors are disclosed, along with methods for producing the novel polypeptides by cultivating such transformed host cells. Soluble forms of the 4-1BB-L or 4-1BB polypeptides are derived from the extracellular domains thereof.
    Type: Grant
    Filed: May 6, 1994
    Date of Patent: October 7, 1997
    Assignee: Immunex Corporation
    Inventors: Raymond G. Goodwin, Craig A. Smith, Mark R. Alderson
  • Patent number: 5620889
    Abstract: The present invention provides a panel of monoclonal antibodies and binding proteins which specifically bind to human Fas antigen. Some of the antibodies and binding proteins are capable of stimulating T cell proliferation, inhibiting binding of anti-Fas CH-11 monoclonal antibody to cells expressing Fas antigen, blocking anti-Fas CH-11 monoclonal antibody-mediated lysis of cells, and blocking Fas ligand-mediated lysis of cells. The invention also provides for therapeutic compositions comprising the monoclonal antibodies.
    Type: Grant
    Filed: October 13, 1994
    Date of Patent: April 15, 1997
    Assignee: Immunex Corporation
    Inventors: David H. Lynch, Mark R. Alderson